RxDoctor Payments Data

Jessica Walia, MD

Ophthalmology · Saint Louis, MONPI 1134625627

Payments from drug & device makers

$1,299in general payments, 2019–2025

Across 20 payments — averaging $64.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$480
  • Sight Sciences, Inc.$249
  • AbbVie$225
  • Bausch & Lomb Americas Inc.$137
  • Mallinckrodt Hospital Products Inc.$98
  • Glaukos Corporation$49
  • plus $61 from 2 others

What the payments were for

  • Food & beverage$1,10185%
  • Education$19815%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,299 in reported general payments places this provider in the 45th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$88,237
Medicare patients
196
Services billed
576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ValacyclovirValacyclovir Hcl151$15,348
Prednisolone Acetate342$13,093
Loteprednol Etabonate62$8,892
XiidraLifitegrast12$8,818
MoxifloxacinMoxifloxacin Hcl238$8,606
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$3,603
Fluorometholone31$2,325
Timolol Maleate51$1,839
Ofloxacin110$1,613
Brimonidine Tartrate81$830
Latanoprost104$777
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat65$687
Mycophenolate Mofetil13$463
Acyclovir16$397
Dorzolamide Hcl13$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$137$8,81812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →